About this episode

Dr. Tom Elliott discusses the impact of GLP-1 therapies on obesity, diabetes, and metabolic health.

Dr. Tom Elliott has spent more than four decades at the forefront of diabetes, endocrinology, and metabolic health. He is the founder and medical director of BC Diabetes, an associate professor at UBC, and has been involved in more than 20 pharmaceutical clinical trials exploring the future of obesity, diabetes, and GLP-1 therapies. In this episode, Dr. Elliott breaks down why obesity, insulin resistance, and prediabetes have exploded across modern society, and why many founders and high performers are quietly damaging their metabolic health through stress, poor sleep, alcohol, sedentary work, and overstimulation. We explore the science behind Ozempic, GLP-1 agonists, retatrutide, testosterone decline, fertility, fasting, aging, addiction, and the future of preventative medicine. Dr. Elliott also explains why some patients in clinical trials “begged to stop” after losing too much weight, and how these drugs may extend far beyond weight loss into addiction recovery and longevity research. You will learn: Why more than 150 million Americans may be prediabetic What GLP-1 drugs actually do inside the body Why Ozempic is affecting fertility, appetite, and addiction How stress and…

Explore listener stats, chart rankings, contacts and more on the Traction Podcast podcast page.